Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COUGH-1 first-in-human ABNCoV2 vaccine trial
NL-OMON50898Phase 1Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of abncov2 and MF59C.1 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Related Grade 3 adverse events and serious adverse events and ABNCoV2-specific antibody concentration at day 14 after first vaccination. Started Mar 2021; status: active, not recruiting.
02
Drugs
abncov2MF59C.1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50898.